To evaluate the cost-effectiveness of the Demands and Capacities Model based treatment (Dutch standard) compared to the Lidcombe programme for early stuttering intervention.Follow-up: Long-term outcome, taking into account recent genetic findings.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
spraakstoornis
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The percentage of recovered children at 18 months post randomisation, frequency
of stuttering and severity ratings, Child Health Questionnaire, costs for a
recovered child.
Follow-up measurement: idem but > 2;6 years later. Also, disease specific
questionnaire will eb fillid in by the children (OASES).
Secondary outcome
Health Utility Index, Child Behaviour Check List
Follow-up measurment: idem, but > 2;6 years later. Also: the questioannaires
with Child's versions (HUI-3, TAPQOL, EQ-VAS), will be filled in by the
children themselves. Besides, genetic mutations related to stuttering will be
investigated.
Background summary
Currently, treatment is provided to all pre-school stuttering children, to
prevent stuttering becoming a chronic, handicapping condition in some of them.
In the Netherlands, most children are treated with the Dutch standard, the DCM.
Experienced clinicians spend about 9 sessions of treatment for each child in
the Demands and Capacities based treatment. Recently, the Australian standard
treatment, the Lidcombe Programme has been introduced in the Netherlands. The
lidcombe Programma takes mostly at least about 18 sessions, so twice as much.
But, the clinicail impression is that the results with the Lidcombe Programme
are significanty better. Yet, about 50 clinicians have been trained to deliver
treatment along the LP approach also. The difference in empirical support for
LP and DCM suggests that in the long-term, LP might be more cost-effective than
the current standard, DCM: the proportion of pre-school stuttering children
that not only decrease their stuttering frequency but recover from stuttering
after completion of the LP might be higher than for DCM, though, for higher
costs. But, in the long term, for comparable costs. This study therefore
explores the cost-effectiveness of the two treatments.
For the Follow-up measurement:
Long-term follow-up after stuttering treatment is essential for a comprehensive
understanding of the treatment outcome. Furthermore, genes related to
stuttering have been demonstrated recently (Kang et al, 2010). During the
proposed clinical follow-up study, the involvement and clinical relevance of
these (and possibly other) genes will be studied as well.
Study objective
To evaluate the cost-effectiveness of the Demands and Capacities Model based
treatment (Dutch standard) compared to the Lidcombe programme for early
stuttering intervention.
Follow-up: Long-term outcome, taking into account recent genetic findings.
Study design
A pragmatic, open plan, parallel group, randomised trial with blinded outcome
assessment.
Intervention
1. Treatment based on the Demands & Capacities Model
2. Lidcombe Programme of early stuttering intervention.
Study burden and risks
Maximum of 8,5 hours for filling in questionaires and making audio-recordings
at home by the parents.
Follow-up: additional 2,5 hours.
Wytemaweg 80
Rotterdam 3015 CN
NL
Wytemaweg 80
Rotterdam 3015 CN
NL
Listed location countries
Age
Inclusion criteria
age at recruitment 3-6 years, frequency of stuttering at least 3.3% Stuttering Like Disfluencies , type of Stuttering Like Disfluencies cf. Yairi & Ambrose ( 2005), and proficiency in Dutch for children and parents
Exclusion criteria
onset of stuttering in the six months before recruitment, treatment for stuttering during the previous 12 months, and diagnosed neurological, learning, emotional or behavioral disorder.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL16180.078.07 |